Body mass index, disease duration and tumor necrosis factor inhibitor history predict reduced ustekinumab response in Chinese psoriasis patients: A real-world study
Background: Ustekinumab, as a monoclonal antibody against interleukin (IL)-12 and IL-23, gets approved in China since 2019, therefore fewstudies report the application of ustekinumab in treating Chinese psoriasis patients in the real clinical settings until now. Aims: Thus, this study aimed to evalu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wolters Kluwer Medknow Publications,
2021-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|